Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TfR1 antagonists(Transferrin receptor protein 1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Preclinical | - | - |